Comparative Pharmacology
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XIFAXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XIFAXAN.
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) vs XIFAXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
Rifaximin is a non-systemic, gut-selective antibiotic that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby reducing bacterial overgrowth and altering gut microbiota composition.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
550 mg orally twice daily for traveler's diarrhea; 550 mg orally three times daily for hepatic encephalopathy.
None Documented
None Documented
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
The terminal elimination half-life for rifaximin after oral administration ranges from 1.8 to 10 hours, with a mean of approximately 6 hours. The half-life is extended in hepatic impairment due to reduced clearance, and no dosage adjustment is recommended for renal impairment.
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Rifaximin is primarily eliminated unchanged in feces via biliary excretion (approximately 97% of an oral dose). Renal excretion of unchanged drug accounts for <0.4% of the dose. Fecal elimination is the major route.
Category D/X
Category C
Antibiotic
Antibiotic